Therapeutic Asset Ratings

91,565 assets7,904 sponsors3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Remimazolam Major Depressive Disorder	Yeongseok Yun	P4	BB (69)
Remimazolam Schizoaffective Disorder	Yeongseok Yun	P4	BB (69)
Remimazolam Schizophrenia	Yeongseok Yun	P4	BB (69)
Rilpivirine Fatty Liver Disease	Fundacion SEIMC-GESIDA	P4	BB (69)
Rilpivirine HIV Infectious Disease	Fundacion SEIMC-GESIDA	P4	BB (69)
Rimegepant Hyperacusis	Pfizer	P4	BB (69)
Rimegepant Photosensitivity Disease	Pfizer	P4	BB (69)
Rocuronium Ion Neuromuscular Junction Disease	Merck Sharp & Dohme LLC	P4	BB (69)
Ropivacaine Developmental Dysplasia Of The Hip	University of California, Los Angeles	P4	BB (69)
Ropivacaine Childhood Acute Lymphoblastic Leukemia	Yilin Zhao	P4	BB (69)
Rosuvastatin Abdominal Obesity-Metabolic Syndrome	Hamdard University	P4	BB (69)
Ruxolitinib Acquired Polycythemia Vera	University of Washington	P4	BB (69)
Selenium Chronic Prostatitis	Clinica Urologica Molinette - Città della Saliute e della Scienza	P4	BB (69)
Semaglutide Pseudotumor Cerebri	Rigmor Højland Jensen	P4	BB (69)
Semaglutide Intracranial Hypertension	Rigmor Højland Jensen	P4	BB (69)
Semaglutide Optic Papillitis	Rigmor Højland Jensen	P4	BB (69)
Silymarin Metabolic Dysfunction-Associated Steatotic Liver Disease	University Hospitals Cleveland Medical Center	P4	BB (69)
Sitagliptin Cirrhosis Of Liver	Kafrelsheikh University	P4	BB (69)
Sitagliptin Lewy Body Dementia	Mayo Clinic	P4	BB (69)
Sitagliptin Abdominal Obesity-Metabolic Syndrome	Hamdard University	P4	BB (69)
Sitagliptin Parkinson Disease	Mayo Clinic	P4	BB (69)
Spironolactone Cognitive Disorder	Emory University	P4	BB (69)
Tacrolimus Lymphoma	National Cancer Institute (NCI)	P4	BB (69)
Tadalafil Abdominal Obesity-Metabolic Syndrome	Kafrelsheikh University	P4	BB (69)
Tafamidis Amyloidosis	Pfizer	P4	BB (69)

Showing 3001 to 3025 of 42,286 assets

PreviousPage 121 of 1692Next